We were pleased to see the study by Drs Shahid and Graba 1 documenting (again) the low yield from the routine performance of blood typing and direct antibody testing (DAT) on infants of mothers with blood type O. 2, 3 It is important to note, however, that the Loyola investigators performed a predischarge total serum bilirubin (TSB) measurement at age 24 h on all infants. They don't provide additional details regarding the risk assessment they performed, but one assumes that they utilized the predischarge TSB as a key component of this assessment.
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We stopped doing a blood type and DAT on infants of group O mothers some 20 years ago but we have measured the transcutaneous bilirubin (TcB) daily on all newborns since 1990. There are now several studies confirming that the predischarge, hour specific, bilirubin measurement, together with the infant's gestational age, provides the information we need to allow an accurate and clinically relevant prediction of the risk, or lack of risk, of subsequent hyperbilirubinemia. [4] [5] [6] [7] Infants with ABO hemolytic disease typically develop early jaundice. Of ABO incompatible DAT positive infants who developed a TSB above the 95th percentile, 8 67% did so within the first 24 h 9 and only 1/85 such infants developed hyperbilirubinemia after age 48 h. 9 Thus, appropriate clinical monitoring and universal TSB/TcB screening should identify early jaundice and the need for blood typing and DAT testing. Although ABO incompatibility (with or without a positive DAT) has been documented in some 20% of infants with kernicterus, 10,11 it accounts for less than 4% of infants who are readmitted for phototherapy. [12] [13] [14] As the authors note, the 2004 AAP guidelines recommend that 'it is an option to test the cord blood for the infant's blood type and DAT, but it is not required provided that there is appropriate surveillance, risk assessment before discharge, and follow-up. ' 15 As long as we comply with this AAP recommendation, routine testing of the blood type and DAT in infants of group O mothers can safely be abandoned. 
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